| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Marrow Transplantation | 58 | 2011 | 2765 | 2.080 |
Why?
|
| B-Lymphocytes | 91 | 2008 | 4665 | 2.060 |
Why?
|
| Clonal Anergy | 20 | 2014 | 169 | 2.000 |
Why?
|
| Football | 11 | 2021 | 460 | 1.640 |
Why?
|
| T-Lymphocytes | 85 | 2018 | 10180 | 1.620 |
Why?
|
| Lymphocyte Activation | 77 | 2014 | 5524 | 1.570 |
Why?
|
| Antigens, Neoplasm | 58 | 2007 | 1988 | 1.540 |
Why?
|
| Lymphoma, Non-Hodgkin | 32 | 2005 | 1381 | 1.370 |
Why?
|
| Antigens, CD | 51 | 2011 | 4026 | 1.280 |
Why?
|
| Antigen-Presenting Cells | 27 | 2011 | 973 | 1.240 |
Why?
|
| Antigens, Surface | 48 | 1993 | 1663 | 1.210 |
Why?
|
| Lymphoma, Follicular | 16 | 2007 | 435 | 1.140 |
Why?
|
| Bone Marrow Purging | 17 | 2007 | 109 | 1.120 |
Why?
|
| T-Lymphocytes, Cytotoxic | 22 | 2012 | 1821 | 1.000 |
Why?
|
| Isoantigens | 13 | 2014 | 567 | 0.960 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 28 | 2004 | 318 | 0.940 |
Why?
|
| Lymphoma | 37 | 2005 | 1877 | 0.910 |
Why?
|
| Immunotoxins | 13 | 2000 | 179 | 0.900 |
Why?
|
| Telomerase | 7 | 2008 | 730 | 0.880 |
Why?
|
| Immunoconjugates | 15 | 2012 | 901 | 0.850 |
Why?
|
| Leukemia | 26 | 2018 | 1511 | 0.810 |
Why?
|
| Antigens, Differentiation | 16 | 2000 | 927 | 0.770 |
Why?
|
| Membrane Glycoproteins | 22 | 2011 | 3768 | 0.760 |
Why?
|
| Antibodies, Monoclonal | 83 | 2011 | 9274 | 0.750 |
Why?
|
| Interleukin-2 | 27 | 2012 | 1904 | 0.740 |
Why?
|
| CD8-Positive T-Lymphocytes | 14 | 2014 | 4479 | 0.680 |
Why?
|
| Cancer Vaccines | 6 | 2008 | 1023 | 0.670 |
Why?
|
| HLA-A2 Antigen | 10 | 2008 | 213 | 0.620 |
Why?
|
| Ricin | 9 | 2011 | 72 | 0.580 |
Why?
|
| Transplantation, Autologous | 33 | 2011 | 2124 | 0.580 |
Why?
|
| Lymphoma, B-Cell | 10 | 2011 | 931 | 0.550 |
Why?
|
| Burkitt Lymphoma | 11 | 2010 | 327 | 0.530 |
Why?
|
| Antigen Presentation | 11 | 2007 | 1284 | 0.530 |
Why?
|
| CD4-Positive T-Lymphocytes | 14 | 2018 | 4386 | 0.510 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 17 | 2004 | 906 | 0.490 |
Why?
|
| HLA-A Antigens | 8 | 2008 | 231 | 0.480 |
Why?
|
| Leukemia, Lymphoid | 19 | 1987 | 315 | 0.480 |
Why?
|
| Tumor Cells, Cultured | 27 | 2008 | 6314 | 0.460 |
Why?
|
| Leukemia, B-Cell | 4 | 1999 | 86 | 0.450 |
Why?
|
| Dendritic Cells | 12 | 2008 | 2725 | 0.450 |
Why?
|
| Occupational Health | 1 | 2019 | 809 | 0.430 |
Why?
|
| Histocompatibility Antigens Class II | 21 | 2002 | 1475 | 0.420 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2008 | 903 | 0.420 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 4 | 2005 | 257 | 0.410 |
Why?
|
| Interferon-gamma | 15 | 2012 | 3206 | 0.390 |
Why?
|
| Polymerase Chain Reaction | 16 | 1999 | 6171 | 0.390 |
Why?
|
| Bone Marrow | 23 | 2006 | 2948 | 0.380 |
Why?
|
| Cell Adhesion Molecules | 7 | 2001 | 1602 | 0.380 |
Why?
|
| Interleukin-4 | 15 | 2011 | 1147 | 0.370 |
Why?
|
| Vaccines, Subunit | 2 | 2008 | 168 | 0.370 |
Why?
|
| Immunologic Memory | 7 | 2011 | 1348 | 0.370 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2005 | 1519 | 0.360 |
Why?
|
| Oligodeoxyribonucleotides | 3 | 2008 | 708 | 0.360 |
Why?
|
| Health Surveys | 2 | 2019 | 4037 | 0.350 |
Why?
|
| Interleukins | 10 | 2012 | 791 | 0.350 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 8 | 2005 | 1596 | 0.350 |
Why?
|
| Immune Tolerance | 10 | 2014 | 2258 | 0.350 |
Why?
|
| Athletes | 4 | 2020 | 1093 | 0.330 |
Why?
|
| Epitopes | 20 | 2012 | 2571 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2007 | 11524 | 0.330 |
Why?
|
| Proto-Oncogene Proteins | 11 | 2002 | 4554 | 0.320 |
Why?
|
| Lymphoid Tissue | 12 | 1992 | 455 | 0.300 |
Why?
|
| Immunoglobulins | 7 | 2011 | 881 | 0.300 |
Why?
|
| Humans | 302 | 2021 | 744343 | 0.300 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2008 | 1270 | 0.290 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 12 | 2018 | 5442 | 0.290 |
Why?
|
| Immunotherapy | 16 | 2011 | 4445 | 0.290 |
Why?
|
| HLA-DR7 Antigen | 6 | 1996 | 27 | 0.290 |
Why?
|
| RNA, Complementary | 1 | 2006 | 45 | 0.280 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2006 | 39 | 0.280 |
Why?
|
| Whole-Body Irradiation | 12 | 2007 | 449 | 0.280 |
Why?
|
| Translocation, Genetic | 9 | 1998 | 1420 | 0.280 |
Why?
|
| Cyclophosphamide | 17 | 2007 | 2242 | 0.270 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 1998 | 222 | 0.270 |
Why?
|
| Anemia, Aplastic | 3 | 2005 | 226 | 0.260 |
Why?
|
| Receptors, Antigen, T-Cell | 14 | 2003 | 2540 | 0.260 |
Why?
|
| Globins | 1 | 2006 | 415 | 0.260 |
Why?
|
| Flow Cytometry | 24 | 2014 | 5974 | 0.260 |
Why?
|
| Clone Cells | 18 | 2003 | 1692 | 0.260 |
Why?
|
| Immunophenotyping | 11 | 2004 | 1880 | 0.250 |
Why?
|
| Cell Adhesion | 9 | 1999 | 3144 | 0.250 |
Why?
|
| Lymphocyte Culture Test, Mixed | 10 | 2011 | 517 | 0.250 |
Why?
|
| Hematopoietic Stem Cells | 20 | 2003 | 3386 | 0.250 |
Why?
|
| Interleukin-7 | 6 | 2004 | 142 | 0.250 |
Why?
|
| Receptors, Interleukin-2 | 8 | 1996 | 573 | 0.250 |
Why?
|
| Brain Concussion | 3 | 2020 | 1320 | 0.240 |
Why?
|
| Cell Separation | 12 | 2004 | 1751 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 11 | 2006 | 1434 | 0.240 |
Why?
|
| T-Lymphocyte Subsets | 7 | 2003 | 1838 | 0.240 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2005 | 349 | 0.240 |
Why?
|
| Lymphocyte Depletion | 8 | 1998 | 608 | 0.230 |
Why?
|
| Leukocytes, Mononuclear | 7 | 2014 | 1836 | 0.230 |
Why?
|
| Neoplastic Stem Cells | 11 | 2004 | 1376 | 0.230 |
Why?
|
| 3T3 Cells | 8 | 1998 | 1101 | 0.230 |
Why?
|
| Leukemia, Plasma Cell | 3 | 2001 | 48 | 0.220 |
Why?
|
| Tetradecanoylphorbol Acetate | 14 | 1994 | 821 | 0.210 |
Why?
|
| Heat-Shock Proteins | 5 | 1995 | 822 | 0.210 |
Why?
|
| HLA-A3 Antigen | 1 | 2001 | 34 | 0.210 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 1997 | 648 | 0.200 |
Why?
|
| Transcription, Genetic | 9 | 2008 | 7722 | 0.200 |
Why?
|
| Genes, MHC Class II | 5 | 2000 | 457 | 0.200 |
Why?
|
| Signal Transduction | 23 | 2012 | 23403 | 0.200 |
Why?
|
| Palatine Tonsil | 8 | 1999 | 193 | 0.200 |
Why?
|
| Cell Cycle | 14 | 2011 | 2967 | 0.200 |
Why?
|
| Receptors, Very Late Antigen | 2 | 1992 | 74 | 0.200 |
Why?
|
| Graft vs Host Disease | 12 | 2018 | 2957 | 0.200 |
Why?
|
| Cloning, Molecular | 8 | 2005 | 4320 | 0.200 |
Why?
|
| Neoplasms | 18 | 2011 | 21683 | 0.200 |
Why?
|
| Apoptosis | 8 | 2001 | 9727 | 0.200 |
Why?
|
| Cells, Cultured | 29 | 2014 | 19229 | 0.200 |
Why?
|
| Antibodies, Anti-Idiotypic | 6 | 1988 | 349 | 0.190 |
Why?
|
| Autoantigens | 2 | 2003 | 892 | 0.190 |
Why?
|
| Autoantibodies | 3 | 2005 | 2035 | 0.190 |
Why?
|
| Receptors, Immunologic | 6 | 1998 | 1423 | 0.180 |
Why?
|
| Oligopeptides | 1 | 2005 | 1189 | 0.180 |
Why?
|
| Transfection | 15 | 2003 | 5892 | 0.180 |
Why?
|
| Spleen | 20 | 1995 | 2362 | 0.170 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2004 | 2849 | 0.170 |
Why?
|
| Cell Differentiation | 34 | 2011 | 11483 | 0.170 |
Why?
|
| RNA, Messenger | 24 | 2003 | 13033 | 0.170 |
Why?
|
| Cell Communication | 6 | 1994 | 1621 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2006 | 4751 | 0.170 |
Why?
|
| Interleukin-12 | 2 | 1999 | 579 | 0.170 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2008 | 3920 | 0.170 |
Why?
|
| Receptors, Antigen, B-Cell | 10 | 1994 | 548 | 0.170 |
Why?
|
| Combined Modality Therapy | 17 | 2007 | 8642 | 0.170 |
Why?
|
| Lymphocyte Subsets | 3 | 1998 | 315 | 0.170 |
Why?
|
| Genes, bcl-2 | 2 | 2001 | 122 | 0.170 |
Why?
|
| Remission Induction | 11 | 2007 | 2386 | 0.160 |
Why?
|
| Mitogen-Activated Protein Kinases | 7 | 2012 | 1285 | 0.160 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 2008 | 1366 | 0.160 |
Why?
|
| Transplantation, Homologous | 12 | 2018 | 4776 | 0.160 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 3 | 2004 | 166 | 0.160 |
Why?
|
| Baseball | 1 | 2019 | 90 | 0.160 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2001 | 651 | 0.160 |
Why?
|
| Mucin-1 | 3 | 2003 | 543 | 0.160 |
Why?
|
| Cell Line | 36 | 2010 | 15997 | 0.160 |
Why?
|
| Vincristine | 8 | 2007 | 1039 | 0.160 |
Why?
|
| Cytotoxicity, Immunologic | 11 | 2005 | 1369 | 0.160 |
Why?
|
| Molecular Sequence Data | 21 | 2011 | 18111 | 0.150 |
Why?
|
| Preleukemia | 1 | 1997 | 35 | 0.150 |
Why?
|
| Adult | 76 | 2020 | 214055 | 0.150 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2000 | 986 | 0.150 |
Why?
|
| Neoplasm Proteins | 7 | 2007 | 3703 | 0.150 |
Why?
|
| Endothelium | 3 | 2006 | 778 | 0.150 |
Why?
|
| Middle Aged | 60 | 2020 | 213383 | 0.150 |
Why?
|
| Cricetinae | 9 | 1998 | 2472 | 0.150 |
Why?
|
| Hematopoiesis | 8 | 2000 | 2072 | 0.140 |
Why?
|
| Amino Acid Sequence | 18 | 2011 | 13815 | 0.140 |
Why?
|
| Multiple Myeloma | 9 | 2005 | 5181 | 0.140 |
Why?
|
| Complement System Proteins | 9 | 1992 | 795 | 0.140 |
Why?
|
| Radioimmunotherapy | 2 | 1993 | 91 | 0.140 |
Why?
|
| Plasma Cells | 3 | 1985 | 591 | 0.140 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 2 | 2012 | 91 | 0.140 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1996 | 139 | 0.140 |
Why?
|
| Cell Cycle Proteins | 5 | 2004 | 3462 | 0.140 |
Why?
|
| Animals | 81 | 2012 | 168757 | 0.140 |
Why?
|
| HLA-DR Antigens | 8 | 2010 | 645 | 0.140 |
Why?
|
| Erectile Dysfunction | 1 | 2019 | 461 | 0.130 |
Why?
|
| Fluorescent Antibody Technique | 13 | 2001 | 2505 | 0.130 |
Why?
|
| Major Histocompatibility Complex | 4 | 2012 | 936 | 0.130 |
Why?
|
| Influenza A virus | 4 | 2004 | 456 | 0.130 |
Why?
|
| Adjuvants, Immunologic | 3 | 2011 | 1000 | 0.130 |
Why?
|
| Down-Regulation | 4 | 2004 | 3002 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 18 | 4 | 1998 | 245 | 0.130 |
Why?
|
| bcl-2-Associated X Protein | 3 | 2005 | 295 | 0.130 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2011 | 407 | 0.130 |
Why?
|
| Doxorubicin | 9 | 2011 | 2234 | 0.130 |
Why?
|
| Phenotype | 28 | 2011 | 16365 | 0.130 |
Why?
|
| Prednisone | 8 | 2007 | 1574 | 0.130 |
Why?
|
| Cognition Disorders | 2 | 2020 | 4043 | 0.130 |
Why?
|
| Cell Survival | 11 | 2011 | 5882 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 14 | 4 | 1998 | 299 | 0.130 |
Why?
|
| CHO Cells | 7 | 1998 | 1406 | 0.130 |
Why?
|
| Mice | 55 | 2010 | 81183 | 0.130 |
Why?
|
| Lymphocytes | 7 | 2018 | 2617 | 0.130 |
Why?
|
| Transplantation Immunology | 2 | 2012 | 546 | 0.130 |
Why?
|
| Immunosuppressive Agents | 4 | 2012 | 4149 | 0.130 |
Why?
|
| Tissue Donors | 5 | 2018 | 2240 | 0.130 |
Why?
|
| Epitopes, T-Lymphocyte | 5 | 2011 | 880 | 0.120 |
Why?
|
| Gene Expression Regulation | 11 | 2008 | 12072 | 0.120 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2000 | 1086 | 0.120 |
Why?
|
| Leukemia, Myeloid | 7 | 2000 | 707 | 0.120 |
Why?
|
| Protein-Tyrosine Kinases | 5 | 2003 | 2455 | 0.120 |
Why?
|
| Antigens, CD19 | 4 | 2010 | 380 | 0.120 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 1994 | 934 | 0.120 |
Why?
|
| Neoplasm, Residual | 3 | 1997 | 973 | 0.120 |
Why?
|
| Membrane Proteins | 7 | 2005 | 7880 | 0.120 |
Why?
|
| HLA-B7 Antigen | 1 | 1993 | 48 | 0.120 |
Why?
|
| Cell Division | 13 | 2004 | 4568 | 0.120 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2018 | 1352 | 0.120 |
Why?
|
| Immunoglobulin Heavy Chains | 5 | 2005 | 659 | 0.120 |
Why?
|
| Jurkat Cells | 4 | 2005 | 743 | 0.120 |
Why?
|
| Male | 75 | 2020 | 350118 | 0.120 |
Why?
|
| Universities | 1 | 2019 | 956 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2012 | 1038 | 0.120 |
Why?
|
| MART-1 Antigen | 3 | 2011 | 64 | 0.110 |
Why?
|
| Blotting, Northern | 7 | 2003 | 1581 | 0.110 |
Why?
|
| Recurrence | 10 | 2007 | 8340 | 0.110 |
Why?
|
| Lymphocyte Transfusion | 2 | 2018 | 236 | 0.110 |
Why?
|
| GTP-Binding Proteins | 1 | 1997 | 970 | 0.110 |
Why?
|
| Exercise Tolerance | 1 | 2018 | 770 | 0.110 |
Why?
|
| Receptors, Interleukin-21 | 2 | 2012 | 33 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 6 | 2005 | 323 | 0.110 |
Why?
|
| Up-Regulation | 8 | 2012 | 4217 | 0.110 |
Why?
|
| Cognition | 2 | 2020 | 6770 | 0.110 |
Why?
|
| Recombinant Proteins | 7 | 1998 | 6622 | 0.110 |
Why?
|
| Bone Marrow Cells | 15 | 2004 | 2513 | 0.110 |
Why?
|
| Immunologic Techniques | 1 | 1992 | 218 | 0.100 |
Why?
|
| Mortality | 2 | 2019 | 2864 | 0.100 |
Why?
|
| B-Cell Activation Factor Receptor | 1 | 2011 | 13 | 0.100 |
Why?
|
| Quality of Life | 4 | 2020 | 12804 | 0.100 |
Why?
|
| Interleukin-1 | 3 | 1997 | 1263 | 0.100 |
Why?
|
| Peptide Fragments | 5 | 2008 | 5097 | 0.100 |
Why?
|
| Herpesvirus 4, Human | 4 | 2003 | 1041 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2003 | 2133 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2003 | 3772 | 0.100 |
Why?
|
| Hodgkin Disease | 4 | 1997 | 1415 | 0.100 |
Why?
|
| Transmembrane Activator and CAML Interactor Protein | 1 | 2011 | 56 | 0.100 |
Why?
|
| Gene Rearrangement | 3 | 1996 | 1179 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1992 | 323 | 0.100 |
Why?
|
| HLA Antigens | 9 | 2012 | 1381 | 0.090 |
Why?
|
| Occupational Diseases | 1 | 2019 | 1471 | 0.090 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2011 | 98 | 0.090 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1992 | 294 | 0.090 |
Why?
|
| Female | 76 | 2018 | 380194 | 0.090 |
Why?
|
| Immunity, Cellular | 6 | 1997 | 1607 | 0.090 |
Why?
|
| RNA | 2 | 2005 | 2749 | 0.090 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2011 | 215 | 0.090 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2011 | 140 | 0.090 |
Why?
|
| CD40 Ligand | 3 | 2001 | 526 | 0.090 |
Why?
|
| Antigens, Viral | 4 | 2004 | 1035 | 0.090 |
Why?
|
| Athletic Injuries | 1 | 2020 | 1154 | 0.090 |
Why?
|
| Antigens | 4 | 1990 | 1466 | 0.090 |
Why?
|
| Microspheres | 4 | 2004 | 777 | 0.090 |
Why?
|
| Life Tables | 5 | 1997 | 370 | 0.090 |
Why?
|
| Time Factors | 21 | 2011 | 40075 | 0.090 |
Why?
|
| Hematologic Neoplasms | 3 | 2008 | 1832 | 0.090 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2005 | 627 | 0.090 |
Why?
|
| Treatment Outcome | 20 | 2011 | 63114 | 0.090 |
Why?
|
| Protein Kinases | 2 | 2008 | 1640 | 0.090 |
Why?
|
| Interphase | 3 | 1986 | 226 | 0.090 |
Why?
|
| DNA-Binding Proteins | 7 | 2005 | 9648 | 0.090 |
Why?
|
| Antibody Specificity | 3 | 2003 | 1095 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 5 | 2004 | 1799 | 0.090 |
Why?
|
| Cell Proliferation | 9 | 2012 | 10481 | 0.090 |
Why?
|
| DNA, Neoplasm | 2 | 1996 | 1758 | 0.090 |
Why?
|
| Cyclin D1 | 2 | 2008 | 463 | 0.090 |
Why?
|
| Cell Movement | 4 | 2011 | 5217 | 0.080 |
Why?
|
| Chemokines, CC | 2 | 2001 | 291 | 0.080 |
Why?
|
| Transplantation Conditioning | 6 | 2018 | 1598 | 0.080 |
Why?
|
| Aged | 29 | 2020 | 163280 | 0.080 |
Why?
|
| Self Report | 4 | 2021 | 3558 | 0.080 |
Why?
|
| Testosterone | 1 | 2019 | 2420 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 15 | 1995 | 6386 | 0.080 |
Why?
|
| Antibodies, Neoplasm | 3 | 1992 | 286 | 0.080 |
Why?
|
| Disease-Free Survival | 9 | 2004 | 6895 | 0.080 |
Why?
|
| Antigen-Antibody Reactions | 6 | 1995 | 363 | 0.080 |
Why?
|
| COS Cells | 3 | 2000 | 1161 | 0.080 |
Why?
|
| Phosphorylation | 9 | 2011 | 8436 | 0.080 |
Why?
|
| Antibody Formation | 1 | 1993 | 1402 | 0.080 |
Why?
|
| Chromosome Mapping | 3 | 1994 | 4740 | 0.080 |
Why?
|
| Survival Analysis | 9 | 2011 | 10252 | 0.080 |
Why?
|
| Anxiety | 2 | 2020 | 4297 | 0.080 |
Why?
|
| Multigene Family | 3 | 1998 | 1102 | 0.080 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 1997 | 1861 | 0.080 |
Why?
|
| Hybrid Cells | 6 | 1992 | 441 | 0.080 |
Why?
|
| United States | 10 | 2021 | 69872 | 0.080 |
Why?
|
| Th1 Cells | 2 | 2011 | 1057 | 0.080 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2008 | 233 | 0.080 |
Why?
|
| Th2 Cells | 2 | 2011 | 1061 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2011 | 2938 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2019 | 23338 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 1997 | 1580 | 0.080 |
Why?
|
| bcl-Associated Death Protein | 2 | 1998 | 107 | 0.080 |
Why?
|
| Gene Expression | 11 | 2004 | 7799 | 0.080 |
Why?
|
| STAT3 Transcription Factor | 1 | 2012 | 873 | 0.080 |
Why?
|
| Monocytes | 6 | 2004 | 2596 | 0.080 |
Why?
|
| Prognosis | 16 | 2007 | 29063 | 0.080 |
Why?
|
| Cell Transformation, Viral | 3 | 2003 | 565 | 0.070 |
Why?
|
| Hot Temperature | 2 | 1992 | 1354 | 0.070 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2008 | 212 | 0.070 |
Why?
|
| Carrier Proteins | 4 | 2005 | 5021 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 2 | 1997 | 116 | 0.070 |
Why?
|
| Immunodominant Epitopes | 2 | 2005 | 267 | 0.070 |
Why?
|
| DNA Fragmentation | 2 | 1997 | 242 | 0.070 |
Why?
|
| Semaphorins | 2 | 1998 | 101 | 0.070 |
Why?
|
| Histocompatibility | 2 | 1999 | 330 | 0.070 |
Why?
|
| Feasibility Studies | 3 | 2005 | 5078 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 1997 | 2916 | 0.070 |
Why?
|
| Colony-Forming Units Assay | 5 | 2003 | 356 | 0.070 |
Why?
|
| Mitogens | 4 | 1996 | 232 | 0.070 |
Why?
|
| Genomics | 1 | 2002 | 5720 | 0.070 |
Why?
|
| Galectin 3 | 1 | 2008 | 227 | 0.070 |
Why?
|
| Phytohemagglutinins | 4 | 1996 | 170 | 0.070 |
Why?
|
| Survival Rate | 7 | 2008 | 12788 | 0.070 |
Why?
|
| Janus Kinase 3 | 3 | 2011 | 78 | 0.070 |
Why?
|
| Base Sequence | 10 | 1999 | 12797 | 0.070 |
Why?
|
| Thalassemia | 2 | 2005 | 273 | 0.070 |
Why?
|
| Antibodies | 8 | 2003 | 2460 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2011 | 2109 | 0.070 |
Why?
|
| bcl-X Protein | 2 | 1998 | 411 | 0.070 |
Why?
|
| Biotinylation | 1 | 2006 | 179 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2019 | 9146 | 0.070 |
Why?
|
| NF-kappa B | 3 | 2011 | 2499 | 0.070 |
Why?
|
| Thymopoietins | 1 | 2005 | 10 | 0.070 |
Why?
|
| Blotting, Western | 4 | 2011 | 5179 | 0.070 |
Why?
|
| DNA, Complementary | 2 | 2003 | 2050 | 0.070 |
Why?
|
| Cardiovascular Diseases | 4 | 2019 | 15165 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 3 | 2005 | 1061 | 0.070 |
Why?
|
| Biomimetics | 1 | 2007 | 172 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2005 | 6773 | 0.070 |
Why?
|
| Mental Health | 1 | 2019 | 3019 | 0.070 |
Why?
|
| Pregnancy Proteins | 1 | 2006 | 229 | 0.060 |
Why?
|
| Carcinoma | 1 | 1996 | 2375 | 0.060 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1985 | 82 | 0.060 |
Why?
|
| Follow-Up Studies | 10 | 2019 | 39050 | 0.060 |
Why?
|
| ras Proteins | 2 | 2002 | 1060 | 0.060 |
Why?
|
| Antineoplastic Agents | 6 | 2004 | 13695 | 0.060 |
Why?
|
| Receptors, Complement | 4 | 1991 | 264 | 0.060 |
Why?
|
| Lymph Nodes | 6 | 1998 | 3474 | 0.060 |
Why?
|
| K562 Cells | 3 | 2012 | 634 | 0.060 |
Why?
|
| Adoptive Transfer | 2 | 2011 | 844 | 0.060 |
Why?
|
| Cyclins | 3 | 2002 | 603 | 0.060 |
Why?
|
| Viral Matrix Proteins | 2 | 2011 | 186 | 0.060 |
Why?
|
| Alleles | 3 | 2011 | 6933 | 0.060 |
Why?
|
| Growth Substances | 4 | 1994 | 784 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 1997 | 3523 | 0.060 |
Why?
|
| Leucovorin | 1 | 2005 | 628 | 0.060 |
Why?
|
| Receptors, Interleukin | 1 | 2004 | 245 | 0.060 |
Why?
|
| Infusions, Intravenous | 3 | 1999 | 2274 | 0.060 |
Why?
|
| Depression | 2 | 2020 | 7766 | 0.060 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2003 | 95 | 0.060 |
Why?
|
| Melanoma | 4 | 2011 | 5510 | 0.060 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2003 | 138 | 0.060 |
Why?
|
| Interleukin-15 | 3 | 2011 | 184 | 0.060 |
Why?
|
| ADP-Ribosylation Factors | 1 | 2003 | 133 | 0.050 |
Why?
|
| Cyclin-Dependent Kinases | 3 | 2002 | 671 | 0.050 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2005 | 675 | 0.050 |
Why?
|
| Interferon-beta | 1 | 2004 | 323 | 0.050 |
Why?
|
| rap1 GTP-Binding Proteins | 1 | 2002 | 60 | 0.050 |
Why?
|
| Receptors, Opioid | 1 | 2003 | 155 | 0.050 |
Why?
|
| Cytokines | 9 | 2012 | 7322 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 6 | 2012 | 2988 | 0.050 |
Why?
|
| Antigens, CD34 | 3 | 2018 | 657 | 0.050 |
Why?
|
| Camptothecin | 1 | 2005 | 576 | 0.050 |
Why?
|
| Receptor, erbB-2 | 2 | 2002 | 2416 | 0.050 |
Why?
|
| Serum Amyloid A Protein | 1 | 1982 | 121 | 0.050 |
Why?
|
| Models, Biological | 5 | 1999 | 9583 | 0.050 |
Why?
|
| Binding Sites, Antibody | 4 | 1998 | 349 | 0.050 |
Why?
|
| Bacterial Infections | 3 | 1996 | 1401 | 0.050 |
Why?
|
| Cytotoxicity Tests, Immunologic | 3 | 1997 | 329 | 0.050 |
Why?
|
| Enzyme Activation | 4 | 2003 | 3701 | 0.050 |
Why?
|
| Guanosine Triphosphate | 2 | 2003 | 321 | 0.050 |
Why?
|
| Molecular Weight | 9 | 1994 | 2255 | 0.050 |
Why?
|
| Peptides | 3 | 2004 | 4409 | 0.050 |
Why?
|
| Ciprofloxacin | 2 | 1995 | 315 | 0.050 |
Why?
|
| Child | 18 | 2008 | 77709 | 0.050 |
Why?
|
| Gene Library | 1 | 2003 | 1074 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2005 | 1619 | 0.050 |
Why?
|
| Melphalan | 2 | 1995 | 431 | 0.050 |
Why?
|
| Lung Diseases | 1 | 1990 | 1886 | 0.050 |
Why?
|
| Interferon-alpha | 1 | 2004 | 895 | 0.050 |
Why?
|
| Cyclin D2 | 1 | 2000 | 101 | 0.050 |
Why?
|
| Blotting, Southern | 2 | 1991 | 803 | 0.040 |
Why?
|
| Nucleic Acid Hybridization | 3 | 2005 | 1375 | 0.040 |
Why?
|
| Plasmids | 1 | 2005 | 2307 | 0.040 |
Why?
|
| Alternative Splicing | 2 | 1995 | 1117 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2019 | 6600 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2004 | 3870 | 0.040 |
Why?
|
| Retrospective Studies | 11 | 2021 | 77449 | 0.040 |
Why?
|
| Cell Line, Tumor | 5 | 2011 | 16689 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2008 | 1940 | 0.040 |
Why?
|
| Magnetics | 2 | 1993 | 606 | 0.040 |
Why?
|
| Binding, Competitive | 7 | 1991 | 1157 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 1992 | 730 | 0.040 |
Why?
|
| Antibodies, Heterophile | 1 | 1999 | 126 | 0.040 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1999 | 134 | 0.040 |
Why?
|
| Immunoglobulin D | 1 | 1999 | 56 | 0.040 |
Why?
|
| Exons | 2 | 1995 | 2437 | 0.040 |
Why?
|
| Immunoblotting | 3 | 2011 | 1682 | 0.040 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 1991 | 220 | 0.040 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 1999 | 201 | 0.040 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 25043 | 0.040 |
Why?
|
| Thymoma | 1 | 2000 | 186 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2002 | 558 | 0.040 |
Why?
|
| Anemia, Sickle Cell | 2 | 2005 | 1018 | 0.040 |
Why?
|
| Macrophages | 7 | 2002 | 5655 | 0.040 |
Why?
|
| G1 Phase | 1 | 2000 | 415 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2008 | 10943 | 0.040 |
Why?
|
| Disease Progression | 4 | 2007 | 13284 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2011 | 2503 | 0.040 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 1992 | 707 | 0.040 |
Why?
|
| Cyclic AMP | 1 | 2002 | 1472 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2011 | 8428 | 0.040 |
Why?
|
| Incidence | 7 | 2018 | 20947 | 0.040 |
Why?
|
| Embryonal Carcinoma Stem Cells | 1 | 1998 | 20 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2001 | 697 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 2 | 2006 | 2635 | 0.040 |
Why?
|
| Lymphotoxin-alpha | 2 | 1995 | 96 | 0.040 |
Why?
|
| Dexamethasone | 2 | 2011 | 1951 | 0.040 |
Why?
|
| Child, Preschool | 8 | 2008 | 41006 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 1994 | 4420 | 0.040 |
Why?
|
| Isoantibodies | 2 | 1982 | 679 | 0.040 |
Why?
|
| Phosphotyrosine | 2 | 1996 | 457 | 0.040 |
Why?
|
| Antibodies, Blocking | 1 | 1998 | 253 | 0.040 |
Why?
|
| Ligands | 2 | 1997 | 3282 | 0.040 |
Why?
|
| rap GTP-Binding Proteins | 1 | 1997 | 28 | 0.040 |
Why?
|
| ras Guanine Nucleotide Exchange Factors | 1 | 1997 | 34 | 0.040 |
Why?
|
| Thymus Neoplasms | 1 | 2000 | 268 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 1995 | 2942 | 0.040 |
Why?
|
| Immunoglobulin G | 5 | 2005 | 4560 | 0.040 |
Why?
|
| Monophenol Monooxygenase | 1 | 1997 | 69 | 0.040 |
Why?
|
| Hemolysis | 1 | 1999 | 420 | 0.040 |
Why?
|
| Rabbits | 8 | 1994 | 4894 | 0.040 |
Why?
|
| Gene Expression Profiling | 3 | 2008 | 9438 | 0.040 |
Why?
|
| Precipitin Tests | 3 | 2004 | 829 | 0.040 |
Why?
|
| Lentivirus | 1 | 2000 | 501 | 0.040 |
Why?
|
| Coculture Techniques | 2 | 2012 | 1341 | 0.040 |
Why?
|
| Clinical Trials as Topic | 5 | 1994 | 7913 | 0.040 |
Why?
|
| Blood Cells | 3 | 2004 | 309 | 0.040 |
Why?
|
| Myeloablative Agonists | 1 | 2018 | 218 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 1997 | 119 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2011 | 3479 | 0.040 |
Why?
|
| Gene Transfer Techniques | 2 | 2000 | 1224 | 0.040 |
Why?
|
| Receptor Aggregation | 2 | 1993 | 80 | 0.040 |
Why?
|
| Influenza Vaccines | 1 | 2004 | 738 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2002 | 921 | 0.040 |
Why?
|
| Fas Ligand Protein | 1 | 1997 | 216 | 0.040 |
Why?
|
| Half-Life | 3 | 2007 | 661 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2003 | 1301 | 0.040 |
Why?
|
| Genes, Immunoglobulin | 2 | 1996 | 291 | 0.040 |
Why?
|
| Catalytic Domain | 1 | 1999 | 698 | 0.040 |
Why?
|
| Amyloid | 1 | 1982 | 795 | 0.040 |
Why?
|
| Leukemia, Experimental | 2 | 1996 | 246 | 0.040 |
Why?
|
| Caspase 1 | 1 | 1997 | 224 | 0.040 |
Why?
|
| src Homology Domains | 1 | 1997 | 364 | 0.040 |
Why?
|
| Glycosylphosphatidylinositols | 2 | 1998 | 94 | 0.040 |
Why?
|
| Post-Concussion Syndrome | 1 | 2019 | 219 | 0.040 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 1996 | 67 | 0.040 |
Why?
|
| Drug Administration Schedule | 3 | 1999 | 4933 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2008 | 2541 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2000 | 538 | 0.040 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1998 | 279 | 0.040 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2000 | 484 | 0.030 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 1992 | 307 | 0.030 |
Why?
|
| DNA | 5 | 2003 | 7301 | 0.030 |
Why?
|
| Infant | 5 | 2008 | 35136 | 0.030 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 1995 | 434 | 0.030 |
Why?
|
| Risk Factors | 7 | 2020 | 72290 | 0.030 |
Why?
|
| Dimerization | 1 | 1997 | 893 | 0.030 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 1995 | 437 | 0.030 |
Why?
|
| Immunity, Innate | 2 | 2018 | 2958 | 0.030 |
Why?
|
| Gangliosides | 1 | 1996 | 137 | 0.030 |
Why?
|
| Lymphoma, T-Cell | 1 | 1998 | 299 | 0.030 |
Why?
|
| Mutation | 5 | 2005 | 29786 | 0.030 |
Why?
|
| Muromonab-CD3 | 2 | 2012 | 96 | 0.030 |
Why?
|
| Graft Survival | 5 | 2008 | 3737 | 0.030 |
Why?
|
| Phagocytosis | 3 | 2004 | 1539 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 1997 | 1378 | 0.030 |
Why?
|
| Protein Binding | 3 | 2003 | 9386 | 0.030 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 1994 | 236 | 0.030 |
Why?
|
| Immunization, Passive | 2 | 1992 | 623 | 0.030 |
Why?
|
| Killer Cells, Natural | 3 | 1998 | 2133 | 0.030 |
Why?
|
| Vaccines | 1 | 2004 | 822 | 0.030 |
Why?
|
| Breast Neoplasms | 3 | 2004 | 20822 | 0.030 |
Why?
|
| Feedback | 1 | 1999 | 795 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 1997 | 563 | 0.030 |
Why?
|
| Stem Cells | 2 | 1985 | 3567 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 3 | 1989 | 1681 | 0.030 |
Why?
|
| Phosphatidylinositols | 2 | 1995 | 291 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 3 | 2011 | 2699 | 0.030 |
Why?
|
| Proteins | 2 | 1997 | 6103 | 0.030 |
Why?
|
| Genetic Vectors | 2 | 2003 | 3420 | 0.030 |
Why?
|
| Keratinocytes | 1 | 1998 | 798 | 0.030 |
Why?
|
| Tretinoin | 2 | 1995 | 517 | 0.030 |
Why?
|
| Genes | 2 | 1991 | 1893 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 1995 | 261 | 0.030 |
Why?
|
| Stromal Cells | 1 | 1999 | 1355 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2012 | 8324 | 0.030 |
Why?
|
| Cause of Death | 3 | 2019 | 3584 | 0.030 |
Why?
|
| Cell Aggregation | 2 | 1996 | 244 | 0.030 |
Why?
|
| Immune System | 1 | 1999 | 805 | 0.030 |
Why?
|
| Drug Synergism | 2 | 2011 | 1792 | 0.030 |
Why?
|
| Acute Disease | 6 | 2000 | 7149 | 0.030 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 1994 | 111 | 0.030 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 1997 | 581 | 0.030 |
Why?
|
| Infant, Newborn | 4 | 2005 | 25625 | 0.030 |
Why?
|
| Hybridomas | 2 | 1985 | 452 | 0.030 |
Why?
|
| Cyclosporine | 2 | 1994 | 786 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 1993 | 157 | 0.030 |
Why?
|
| Sarcoma, Experimental | 1 | 1993 | 128 | 0.030 |
Why?
|
| Fibroblasts | 2 | 1996 | 4161 | 0.030 |
Why?
|
| Adolescent | 13 | 2011 | 85781 | 0.030 |
Why?
|
| Androstadienes | 1 | 1995 | 346 | 0.030 |
Why?
|
| Monitoring, Immunologic | 1 | 1993 | 100 | 0.030 |
Why?
|
| Melanoma, Experimental | 1 | 1996 | 561 | 0.030 |
Why?
|
| Rosette Formation | 5 | 1984 | 153 | 0.030 |
Why?
|
| Antibody-Producing Cells | 2 | 1985 | 143 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 12354 | 0.030 |
Why?
|
| Chemical Phenomena | 2 | 1985 | 518 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 1994 | 321 | 0.030 |
Why?
|
| Lymphokines | 2 | 1987 | 949 | 0.030 |
Why?
|
| Tetanus Toxoid | 1 | 1993 | 193 | 0.030 |
Why?
|
| Receptors, Complement 3d | 2 | 1991 | 118 | 0.030 |
Why?
|
| HeLa Cells | 1 | 1999 | 3128 | 0.030 |
Why?
|
| Pyrans | 1 | 1993 | 54 | 0.030 |
Why?
|
| Absorption | 3 | 1981 | 248 | 0.030 |
Why?
|
| Reference Values | 2 | 1997 | 4982 | 0.030 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 658 | 0.030 |
Why?
|
| Receptors, Transferrin | 2 | 2004 | 296 | 0.030 |
Why?
|
| Prevalence | 2 | 2019 | 15226 | 0.030 |
Why?
|
| Glucose | 1 | 2004 | 4397 | 0.030 |
Why?
|
| Electroporation | 1 | 1993 | 251 | 0.030 |
Why?
|
| Calcimycin | 1 | 1992 | 222 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 1997 | 1200 | 0.030 |
Why?
|
| Vaccination | 1 | 2004 | 3278 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2003 | 480 | 0.030 |
Why?
|
| Age Factors | 3 | 2005 | 18370 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 1992 | 224 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2003 | 489 | 0.030 |
Why?
|
| Transplantation Chimera | 2 | 2008 | 612 | 0.030 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 57776 | 0.030 |
Why?
|
| Liver Neoplasms | 3 | 2005 | 4253 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2011 | 692 | 0.020 |
Why?
|
| Karyotyping | 3 | 2003 | 1243 | 0.020 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2011 | 40 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2001 | 2915 | 0.020 |
Why?
|
| B-Cell Activating Factor | 1 | 2011 | 119 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 1997 | 1058 | 0.020 |
Why?
|
| Glycolipids | 1 | 1992 | 204 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1992 | 647 | 0.020 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2019 | 944 | 0.020 |
Why?
|
| Chromones | 1 | 2011 | 154 | 0.020 |
Why?
|
| Particle Size | 2 | 2004 | 1642 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 1992 | 418 | 0.020 |
Why?
|
| Chemokine CCL22 | 2 | 2001 | 26 | 0.020 |
Why?
|
| Antigens, Ly | 1 | 1992 | 291 | 0.020 |
Why?
|
| Eukaryotic Initiation Factor-4G | 1 | 2011 | 68 | 0.020 |
Why?
|
| Database Management Systems | 1 | 2012 | 270 | 0.020 |
Why?
|
| Genetic Techniques | 1 | 1993 | 435 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2004 | 648 | 0.020 |
Why?
|
| Mice, Inbred NOD | 2 | 2006 | 1878 | 0.020 |
Why?
|
| Forecasting | 1 | 1999 | 2951 | 0.020 |
Why?
|
| Oligosaccharides | 1 | 1992 | 414 | 0.020 |
Why?
|
| Gallium Radioisotopes | 1 | 1990 | 178 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 2 | 2011 | 1526 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2011 | 130 | 0.020 |
Why?
|
| Neurodegenerative Diseases | 1 | 2019 | 1061 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1992 | 517 | 0.020 |
Why?
|
| Culture Media | 2 | 1990 | 908 | 0.020 |
Why?
|
| Staining and Labeling | 2 | 1996 | 1100 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 1992 | 592 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1993 | 1155 | 0.020 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1990 | 140 | 0.020 |
Why?
|
| Pokeweed Mitogens | 3 | 1984 | 38 | 0.020 |
Why?
|
| Drug Design | 2 | 1992 | 1076 | 0.020 |
Why?
|
| Mice, SCID | 2 | 2006 | 2716 | 0.020 |
Why?
|
| Sirolimus | 2 | 2011 | 1564 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 1999 | 2107 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 1995 | 1072 | 0.020 |
Why?
|
| Kinetics | 4 | 1985 | 6473 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 1996 | 1547 | 0.020 |
Why?
|
| Protein Isoforms | 2 | 2005 | 1730 | 0.020 |
Why?
|
| Immunohistochemistry | 4 | 2011 | 11366 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2001 | 433 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 1996 | 1341 | 0.020 |
Why?
|
| Interleukin-6 | 2 | 1989 | 3200 | 0.020 |
Why?
|
| Biological Factors | 1 | 1990 | 164 | 0.020 |
Why?
|
| Myeloma Proteins | 1 | 1989 | 72 | 0.020 |
Why?
|
| Cohort Studies | 4 | 2005 | 40561 | 0.020 |
Why?
|
| Tacrolimus | 1 | 1993 | 743 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 1993 | 2256 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 2003 | 1801 | 0.020 |
Why?
|
| Receptors, Cell Surface | 2 | 1992 | 2866 | 0.020 |
Why?
|
| Salvage Therapy | 2 | 1994 | 1275 | 0.020 |
Why?
|
| Receptors, Fc | 2 | 1983 | 541 | 0.020 |
Why?
|
| Immunomagnetic Separation | 1 | 2008 | 80 | 0.020 |
Why?
|
| Neprilysin | 3 | 1986 | 439 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1989 | 1085 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2012 | 780 | 0.020 |
Why?
|
| Cell Line, Transformed | 3 | 1996 | 898 | 0.020 |
Why?
|
| Receptors, CCR7 | 1 | 2008 | 108 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 1991 | 572 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 1983 | 1588 | 0.020 |
Why?
|
| Tissue and Organ Procurement | 1 | 1996 | 896 | 0.020 |
Why?
|
| Lymphoproliferative Disorders | 4 | 1990 | 523 | 0.020 |
Why?
|
| Mediastinal Neoplasms | 2 | 1982 | 423 | 0.020 |
Why?
|
| Antigens, CD20 | 1 | 1989 | 199 | 0.020 |
Why?
|
| Cell Count | 2 | 2000 | 1856 | 0.020 |
Why?
|
| Fetus | 3 | 1984 | 1880 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 1989 | 376 | 0.020 |
Why?
|
| Morpholines | 1 | 2011 | 571 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2012 | 705 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 1998 | 3036 | 0.020 |
Why?
|
| Phosphoproteins | 3 | 2011 | 2440 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2012 | 553 | 0.020 |
Why?
|
| Enzyme Inhibitors | 2 | 2011 | 3798 | 0.020 |
Why?
|
| Young Adult | 3 | 2020 | 56430 | 0.020 |
Why?
|
| Cytarabine | 2 | 2000 | 692 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 6993 | 0.020 |
Why?
|
| Lymphocyte Cooperation | 1 | 1986 | 112 | 0.020 |
Why?
|
| Cross-Linking Reagents | 1 | 1989 | 694 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2001 | 3143 | 0.020 |
Why?
|
| Blood Donors | 1 | 2008 | 355 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 1992 | 1276 | 0.020 |
Why?
|
| Bone Marrow Diseases | 1 | 2008 | 231 | 0.020 |
Why?
|
| Pulmonary Fibrosis | 1 | 1990 | 530 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 1996 | 9239 | 0.020 |
Why?
|
| Cell Death | 1 | 1992 | 1706 | 0.020 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2008 | 323 | 0.020 |
Why?
|
| HLA-D Antigens | 2 | 1984 | 134 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2008 | 19905 | 0.020 |
Why?
|
| Phorbols | 2 | 1986 | 43 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2003 | 2839 | 0.020 |
Why?
|
| Chemistry, Physical | 1 | 1985 | 156 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2005 | 191 | 0.020 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2004 | 88 | 0.020 |
Why?
|
| Interferon Type I | 1 | 1989 | 542 | 0.020 |
Why?
|
| 1,2-Dipalmitoylphosphatidylcholine | 1 | 2004 | 43 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 1997 | 5391 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 4 | 1996 | 21827 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2001 | 4262 | 0.020 |
Why?
|
| Substrate Specificity | 2 | 2002 | 1801 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 1504 | 0.020 |
Why?
|
| Interleukin-9 | 1 | 2004 | 63 | 0.020 |
Why?
|
| Galago | 1 | 1984 | 1 | 0.020 |
Why?
|
| Hylobates | 1 | 1984 | 13 | 0.020 |
Why?
|
| Mice, Transgenic | 3 | 2004 | 9734 | 0.020 |
Why?
|
| Aotus trivirgatus | 1 | 1984 | 37 | 0.020 |
Why?
|
| Lemur | 1 | 1984 | 5 | 0.020 |
Why?
|
| Saguinus | 1 | 1984 | 17 | 0.020 |
Why?
|
| Cercopithecidae | 1 | 1984 | 22 | 0.020 |
Why?
|
| Acrylates | 1 | 2004 | 89 | 0.020 |
Why?
|
| Prospective Studies | 4 | 2005 | 53288 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 1992 | 2007 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 365 | 0.020 |
Why?
|
| Cell Membrane | 4 | 2003 | 3748 | 0.020 |
Why?
|
| Quinazolines | 1 | 2011 | 1356 | 0.020 |
Why?
|
| Mice, Inbred C3H | 2 | 1996 | 964 | 0.020 |
Why?
|
| Graft Rejection | 3 | 1996 | 4397 | 0.010 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2006 | 712 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2006 | 964 | 0.010 |
Why?
|
| Microscopy, Video | 1 | 2004 | 245 | 0.010 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2004 | 192 | 0.010 |
Why?
|
| Prostatic Neoplasms | 2 | 2004 | 11124 | 0.010 |
Why?
|
| Autocrine Communication | 1 | 2004 | 171 | 0.010 |
Why?
|
| Depression, Chemical | 2 | 2001 | 191 | 0.010 |
Why?
|
| Pan troglodytes | 1 | 1984 | 229 | 0.010 |
Why?
|
| Mice, Inbred DBA | 2 | 1994 | 642 | 0.010 |
Why?
|
| Plasmacytoma | 1 | 1984 | 183 | 0.010 |
Why?
|
| HLA-DR5 Antigen | 1 | 1982 | 4 | 0.010 |
Why?
|
| DNA Primers | 2 | 1999 | 2892 | 0.010 |
Why?
|
| Lymphatic Diseases | 1 | 1985 | 324 | 0.010 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 2002 | 102 | 0.010 |
Why?
|
| Histocytochemistry | 2 | 1984 | 719 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2005 | 419 | 0.010 |
Why?
|
| U937 Cells | 1 | 2003 | 268 | 0.010 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2004 | 440 | 0.010 |
Why?
|
| Liver | 4 | 1998 | 7474 | 0.010 |
Why?
|
| Phorbol Esters | 1 | 1982 | 111 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 1983 | 315 | 0.010 |
Why?
|
| Glycogen Synthase Kinases | 1 | 2002 | 40 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 1997 | 5853 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 1984 | 741 | 0.010 |
Why?
|
| Macrophage-1 Antigen | 1 | 1983 | 290 | 0.010 |
Why?
|
| Glycoproteins | 4 | 1986 | 2263 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 3 | 2001 | 5867 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 1983 | 549 | 0.010 |
Why?
|
| Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2002 | 67 | 0.010 |
Why?
|
| Monokines | 1 | 1982 | 75 | 0.010 |
Why?
|
| Infectious Mononucleosis | 1 | 1982 | 131 | 0.010 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2002 | 96 | 0.010 |
Why?
|
| Chemokine CCL17 | 1 | 2001 | 23 | 0.010 |
Why?
|
| Haplotypes | 1 | 2008 | 2779 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 2008 | 820 | 0.010 |
Why?
|
| Complement C3 | 1 | 1983 | 461 | 0.010 |
Why?
|
| Smad2 Protein | 1 | 2001 | 156 | 0.010 |
Why?
|
| Sarcoma, Kaposi | 1 | 1984 | 370 | 0.010 |
Why?
|
| Cell-Free System | 1 | 1982 | 344 | 0.010 |
Why?
|
| Neoplasm Transplantation | 2 | 1996 | 2085 | 0.010 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1983 | 482 | 0.010 |
Why?
|
| Flavonoids | 1 | 2004 | 443 | 0.010 |
Why?
|
| Chemistry | 1 | 1981 | 352 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2000 | 38 | 0.010 |
Why?
|
| Macaca mulatta | 2 | 1987 | 2375 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2004 | 693 | 0.010 |
Why?
|
| Population | 1 | 1981 | 142 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 2004 | 588 | 0.010 |
Why?
|
| Smad4 Protein | 1 | 2001 | 163 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2004 | 2557 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2004 | 1137 | 0.010 |
Why?
|
| NAD+ Nucleosidase | 1 | 2000 | 39 | 0.010 |
Why?
|
| Chemotactic Factors | 1 | 2001 | 199 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 1678 | 0.010 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2002 | 494 | 0.010 |
Why?
|
| Japan | 1 | 2005 | 1360 | 0.010 |
Why?
|
| Recombination, Genetic | 2 | 1987 | 1586 | 0.010 |
Why?
|
| Disease | 1 | 1986 | 680 | 0.010 |
Why?
|
| Sezary Syndrome | 1 | 1981 | 76 | 0.010 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2002 | 337 | 0.010 |
Why?
|
| Naphthol AS D Esterase | 1 | 1979 | 14 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2003 | 769 | 0.010 |
Why?
|
| Sjogren's Syndrome | 1 | 1982 | 233 | 0.010 |
Why?
|
| Cell Nucleus | 2 | 2001 | 2969 | 0.010 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2002 | 430 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2003 | 704 | 0.010 |
Why?
|
| Drug Carriers | 1 | 2004 | 693 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1998 | 18029 | 0.010 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 1979 | 98 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1995 | 14722 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1981 | 1386 | 0.010 |
Why?
|
| Horses | 1 | 1980 | 304 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 2004 | 847 | 0.010 |
Why?
|
| Erythropoiesis | 1 | 1983 | 705 | 0.010 |
Why?
|
| Bleomycin | 1 | 2000 | 512 | 0.010 |
Why?
|
| Classification | 1 | 1979 | 129 | 0.010 |
Why?
|
| Mice, Nude | 2 | 1996 | 3689 | 0.010 |
Why?
|
| Leukocytes | 3 | 1983 | 2043 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 2886 | 0.010 |
Why?
|
| Etoposide | 1 | 2000 | 641 | 0.010 |
Why?
|
| Viral Core Proteins | 1 | 1999 | 162 | 0.010 |
Why?
|
| Immune Sera | 2 | 1993 | 641 | 0.010 |
Why?
|
| Antilymphocyte Serum | 1 | 1980 | 492 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2005 | 1530 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1982 | 604 | 0.010 |
Why?
|
| Mitomycins | 1 | 1977 | 47 | 0.010 |
Why?
|
| Binding Sites | 3 | 1996 | 6114 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2005 | 21746 | 0.010 |
Why?
|
| GPI-Linked Proteins | 1 | 1998 | 434 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 1998 | 227 | 0.010 |
Why?
|
| Polymers | 1 | 2004 | 1621 | 0.010 |
Why?
|
| Lymphatic Irradiation | 1 | 1997 | 103 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 1999 | 793 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2001 | 1097 | 0.010 |
Why?
|
| Phylogeny | 1 | 1984 | 2803 | 0.010 |
Why?
|
| Neoplasm Metastasis | 2 | 2003 | 4851 | 0.010 |
Why?
|
| Homozygote | 1 | 1981 | 1785 | 0.010 |
Why?
|
| Freezing | 1 | 1996 | 303 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1985 | 2232 | 0.010 |
Why?
|
| Actins | 1 | 2003 | 2121 | 0.010 |
Why?
|
| Pulmonary Edema | 1 | 1998 | 414 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1996 | 377 | 0.010 |
Why?
|
| Ascitic Fluid | 1 | 1995 | 192 | 0.010 |
Why?
|
| DNA Replication | 1 | 1982 | 1399 | 0.010 |
Why?
|
| DNA Probes | 1 | 1996 | 560 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1996 | 878 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 1981 | 2421 | 0.010 |
Why?
|
| Rats | 1 | 1992 | 24260 | 0.010 |
Why?
|
| Mice, Inbred AKR | 1 | 1994 | 107 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 1977 | 590 | 0.010 |
Why?
|
| Immunocompetence | 1 | 1995 | 137 | 0.010 |
Why?
|
| Receptors, IgE | 1 | 1996 | 389 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1995 | 475 | 0.010 |
Why?
|
| Genomic Library | 1 | 1994 | 193 | 0.010 |
Why?
|
| Myeloblastin | 1 | 1995 | 101 | 0.010 |
Why?
|
| Radionuclide Imaging | 2 | 1990 | 2031 | 0.010 |
Why?
|
| Phosphatidylinositol Phosphates | 1 | 1995 | 209 | 0.010 |
Why?
|
| Thymidine | 1 | 1994 | 310 | 0.010 |
Why?
|
| Fever of Unknown Origin | 1 | 1995 | 93 | 0.010 |
Why?
|
| Polymorphism, Genetic | 2 | 1984 | 4328 | 0.010 |
Why?
|
| Heterozygote | 1 | 1981 | 2804 | 0.010 |
Why?
|
| HLA-DP Antigens | 2 | 1984 | 28 | 0.010 |
Why?
|
| Procainamide | 1 | 1973 | 61 | 0.010 |
Why?
|
| X Chromosome | 1 | 1997 | 814 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 1994 | 279 | 0.010 |
Why?
|
| Mice, Inbred A | 1 | 1993 | 248 | 0.010 |
Why?
|
| Calcineurin | 1 | 1994 | 226 | 0.010 |
Why?
|
| Methotrexate | 1 | 2000 | 1727 | 0.010 |
Why?
|
| Concanavalin A | 1 | 1992 | 191 | 0.010 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 1994 | 249 | 0.010 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 1995 | 436 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1994 | 337 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1996 | 1723 | 0.010 |
Why?
|
| Quinones | 1 | 1992 | 76 | 0.010 |
Why?
|
| Rifabutin | 1 | 1992 | 52 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 1992 | 148 | 0.010 |
Why?
|
| Pregnancy | 2 | 1984 | 29144 | 0.010 |
Why?
|
| Granulocytes | 1 | 1994 | 548 | 0.010 |
Why?
|
| Predictive Value of Tests | 2 | 1998 | 15076 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2001 | 2924 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1995 | 862 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1996 | 2008 | 0.010 |
Why?
|
| Benzoquinones | 1 | 1992 | 201 | 0.010 |
Why?
|
| Mitochondria | 1 | 2004 | 3520 | 0.010 |
Why?
|
| Carmustine | 1 | 1990 | 137 | 0.010 |
Why?
|
| Histocompatibility Antigens | 1 | 1992 | 471 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1994 | 1950 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 1998 | 1179 | 0.010 |
Why?
|
| Galactose | 1 | 1991 | 306 | 0.010 |
Why?
|
| Brain Neoplasms | 2 | 1989 | 8863 | 0.010 |
Why?
|
| Biological Availability | 1 | 1991 | 397 | 0.010 |
Why?
|
| Lactams, Macrocyclic | 1 | 1992 | 320 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1991 | 528 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 1996 | 1813 | 0.010 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 1990 | 107 | 0.010 |
Why?
|
| Tissue Distribution | 2 | 1986 | 2327 | 0.010 |
Why?
|
| Cytogenetics | 1 | 1990 | 203 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1997 | 2382 | 0.010 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1982 | 2104 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 2003 | 13102 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1990 | 768 | 0.010 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1990 | 249 | 0.010 |
Why?
|
| Hepatitis | 1 | 1990 | 227 | 0.010 |
Why?
|
| Chimera | 1 | 1990 | 485 | 0.000 |
Why?
|
| Ovarian Neoplasms | 2 | 1983 | 4838 | 0.000 |
Why?
|
| Herpes Zoster | 1 | 1990 | 264 | 0.000 |
Why?
|
| Tyrosine | 1 | 1992 | 1461 | 0.000 |
Why?
|
| Iodides | 1 | 1987 | 41 | 0.000 |
Why?
|
| Administration, Oral | 1 | 1995 | 3913 | 0.000 |
Why?
|
| Structure-Activity Relationship | 1 | 1992 | 3129 | 0.000 |
Why?
|
| Ammonium Chloride | 1 | 1986 | 74 | 0.000 |
Why?
|
| Calcium | 2 | 1992 | 5756 | 0.000 |
Why?
|
| Thiocyanates | 1 | 1986 | 70 | 0.000 |
Why?
|
| Fluoresceins | 1 | 1986 | 235 | 0.000 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1987 | 417 | 0.000 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 1986 | 225 | 0.000 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1987 | 437 | 0.000 |
Why?
|
| HIV Infections | 1 | 1992 | 16718 | 0.000 |
Why?
|
| Risk | 1 | 1997 | 9687 | 0.000 |
Why?
|
| Algorithms | 1 | 2005 | 13881 | 0.000 |
Why?
|
| Culture Techniques | 1 | 1985 | 554 | 0.000 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2003 | 5221 | 0.000 |
Why?
|
| Complement C3d | 1 | 1983 | 21 | 0.000 |
Why?
|
| HLA-DQ Antigens | 1 | 1984 | 210 | 0.000 |
Why?
|
| Mathematics | 1 | 1985 | 728 | 0.000 |
Why?
|
| Herpesviridae Infections | 1 | 1985 | 277 | 0.000 |
Why?
|
| Iodine Radioisotopes | 1 | 1987 | 1032 | 0.000 |
Why?
|
| Vinblastine | 1 | 1984 | 502 | 0.000 |
Why?
|
| Occipital Lobe | 1 | 1984 | 379 | 0.000 |
Why?
|
| Erythrocytes | 2 | 1983 | 2455 | 0.000 |
Why?
|
| Genotype | 1 | 1997 | 12951 | 0.000 |
Why?
|
| Homeostasis | 1 | 1993 | 3340 | 0.000 |
Why?
|
| Tumor Virus Infections | 1 | 1985 | 452 | 0.000 |
Why?
|
| Lymphocytes, Null | 1 | 1981 | 13 | 0.000 |
Why?
|
| Chemical Precipitation | 1 | 1981 | 179 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1995 | 12026 | 0.000 |
Why?
|
| Cross Reactions | 1 | 1982 | 841 | 0.000 |
Why?
|
| Macromolecular Substances | 1 | 1982 | 1454 | 0.000 |
Why?
|
| Splenectomy | 1 | 1981 | 395 | 0.000 |
Why?
|
| Methionine | 1 | 1981 | 590 | 0.000 |
Why?
|
| Megakaryocytes | 1 | 1983 | 545 | 0.000 |
Why?
|
| Sheep | 1 | 1981 | 1437 | 0.000 |
Why?
|
| Lymphatic Metastasis | 1 | 1986 | 2924 | 0.000 |
Why?
|
| Fluorescent Dyes | 1 | 1986 | 1917 | 0.000 |
Why?
|
| Nucleotidyltransferases | 1 | 1979 | 220 | 0.000 |
Why?
|
| Cytoplasm | 1 | 1981 | 1539 | 0.000 |
Why?
|
| Thymus Gland | 1 | 1979 | 1267 | 0.000 |
Why?
|
| Biotransformation | 1 | 1973 | 168 | 0.000 |
Why?
|
| Isoproterenol | 1 | 1973 | 399 | 0.000 |
Why?
|
| Adipose Tissue | 1 | 1985 | 3279 | 0.000 |
Why?
|
| Peritoneal Dialysis | 1 | 1973 | 146 | 0.000 |
Why?
|
| Epinephrine | 1 | 1973 | 792 | 0.000 |
Why?
|
| Heart Conduction System | 1 | 1973 | 1047 | 0.000 |
Why?
|
| Pacemaker, Artificial | 1 | 1973 | 816 | 0.000 |
Why?
|
| Hypotension | 1 | 1973 | 884 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1973 | 6442 | 0.000 |
Why?
|